Medical network - February 23 this year, Lilly (Eli Lilly), Pfizer (Pfizer), Takeda (Takeda), bristol-myers Squibb (Bristol Myers Squibb) and Gilead (Gilead) will encounter patent cliff, some of these companies support products in the United States will lose patent protection.
FiercePharma combed the ten patent invalidation drugs in 2017 the United States market, the products cover multiple therapeutic areas, including multiple sclerosis (MS), HIV, ED and tumor, total last year reached more than $10 billion in sales in the United States.
Drugs lose market monopoly is not a simple event, often also is affected by the new patent and legal judgment. So in the analysis, FiercePharma not only focus on patent will fail products this year, also considered for patent lawsuits with the great influence of the generic competition.
The U.S. market in 2017 top ten patent medicines
List of the first is the Teva long-acting MS drugs g (Teva) he (Copaxone), the drug is the key to is in a beleaguered Teva products, sales in the United States were about $3.48 billion last year. At present, it is still in the patent court generics challenge. In the year to January, he failed in a number of patent challenges, teva will seek appeal remains to be seen. Analysts pointed out that the company will face a "dangerous" generic competition this year. In mid-february, teva due to report results in the fourth quarter of 2016, if the generics market, he will be robbed g the market share of the $1 billion to $1.3 billion.
Teva, however, now you can relax a little. Momenta companies are working with its partners to Sandoz (Sandoz), the report said the FDA warning letters will delay its g he generic listing process.
Followed, after he is lilly of love (Cialis), according to the forecast EvaluatePharma, the drug sales in 2022 will drop to $2016 in 1.42 billion from $55 million. This year, when love is still expected to retain in the position of "blockbuster", but after that will start to "free fall".
Except when love force, lilly and ADHD drugs choose sida (Strattera) this year with the antithrombotic drug prasugrel (Effient) lose patent protection. Among them, the former to $535 million in sales ranked 10th in the list, to the drug sales are expected to fall to $13 million in 2022. By these three products will lose the market monopoly, and the setback to alzheimer's drug test, lilly said at the end of last year, plans to stop the three drug promotion and the sales job layoffs.
Pfizer of sildenafil (Viagra) and takeda jose carreras (Velcade) on the list were three, four, both in the United States market sales last year were more than $1 billion.
Pfizer's famous blue pills viagra to face generic competition in December of this year, before this, Pfizer continues to vigorously promote the drug. Last year, viagra reaped $1.15 billion in sales in the us market, and it is predicted that it would drop to $188 million by 2022.
Jose carreras estimated sales of $2016 in 1.13 billion, the drug will lose patent protection in November this year, to 2022, it will be nearly $1 billion in market generics "eat". Fresenius (Fresenius) and teva generics has got the FDA approval in advance.
HIV drugs according to the non - the BMS (Sustiva) ranked fifth in the list, sales in the us market for $901 million last year. Teva, Emcure, Strides with Aurobindo generics have get approval in advance.
Novartis (Novartis) also have a product list - good dragon Sandostatin (LAR) patents will expire in December 31, the drug for the treatment of acromegaly and diarrhea associated with specific types of cancer, estimated sales of $2016 in 853 million. However, owing to the high threshold of generic, until 2022 the good dragon sales will remain strong.
And also on the list for Novo Nordisk (Novo Nordisk) performance incentive to the growth of the nords hin (Norditropin SimpleXx), geely's hepatitis b, HIV antiviral tenofovir (Viread), succinic acid and Pfizer's antidepressants to nails rafa sheen (Pristiq).
For gilead, plug gaps on tenofovir sales is very important, because it from generics eroding market share at the same time, the sale of HCV drugs after the great recession. Geely's chief executive said, because the income gap, merger and acquisition activity is quite necessary for the company's growth.
|
